Dr Reddy’s, Merck’s Covid pill partner in India, sees a short-lived boom

And this is despite Dr Reddy’s, one of India’s largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod to produce Merck’s antiviral drug molnupiravir within weeks. The reason: multiple licensees for the Merck drug will cap profits and manufacturing glitches for Sputnik have led to loss of precious time as the world’s second-most populous nation was ramping up its inoculation drive.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3wZ74lr
via IFTTT